
    
      This is a phase 2a, Randomized, Multi-center, Blinded, Paired Psoriasis Lesion, Comparative
      Placebo-Controlled study to evaluate the safety, preliminary efficacy and pharmacokinetics of
      MOL4239 in 30 adult subjects with mild to moderate plaque psoriasis. Eligible subject will
      have a diagnosis of mild to moderate plaque psoriasis affecting 9.9% body surface area (BSA)
      or less, and two designated similar target lesions with a Psoriasis Severity Score of at
      least 6 or higher. Each subject will apply 10% MOL4239 ointment to one target lesion and
      placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days.
    
  